OncoMatch/Clinical Trials/NCT06854653
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Is NCT06854653 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies PTX-100 for ctcl.
Treatment: PTX-100 — This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL). PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles, then 21 day cycle thereafter. Subjects will be treated or followed up, if subjects discontinue treatment, for up to 18 months.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage IB, II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
Has received and failed (or intolerant of) at least 2 prior lines of prior systemic therapy for their disease.
Cannot have received: allogeneic or autologous hematopoietic transplantation
Prior allogeneic or autologous hematopoietic transplantation
Lab requirements
Blood counts
Has adequate bone marrow function.
Kidney function
Has adequate Renal function.
Liver function
Has adequate hepatic function.
Has adequate bone marrow function. Has adequate hepatic function. Has adequate Renal function. Has adequate coagulation function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Comprehensive Cancer Cente · Duarte, California
- University of California Irvine · Irvine, California
- Yale Cancer Center · New Haven, Connecticut
- Dana-Farber Cancer Institute · Boston, Massachusetts
- Rochester Skin Lymphoma Medical Group. PLLC · Rochester, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify